Advertisement

Journal of Gastrointestinal Cancer

, Volume 50, Issue 1, pp 156–159 | Cite as

Giant Hepatic Adenoma in a 12-Year-Old Girl

  • Hemant Kumar Singh
  • Shraddha Patkar
  • A. M. Polnaya
  • Mukta Ramadwar
  • Mahesh GoelEmail author
Case Report
  • 24 Downloads

Background

Hepatic adenomas (HA) are benign tumours and constitute 2% of all the liver tumours with an annual incidence of 3–4 per million in Europe and North America [1]. There has been an increase in incidence owing to increase in the use of oestrogen-based contraceptive medication and increased detection due to widespread use of imaging modalities. The common predisposing factor for hepatic adenoma is the use of oestrogen-based oral contraceptive pills. Here, we present a case of giant hepatic adenoma in a young girl in whom no predisposing factors could be identified.

Case Report

A 12-year-old girl presented with an acute onset of abdominal pain and vomiting for 2 days. She was evaluated elsewhere and was diagnosed to have acute pancreatitis due to elevated amylase (248 U/L, 22–80 U/L) and lipase (1680 U/L, 13–60 U/L) levels. The patient did not have any history of previous hospital admissions or significant medical history. There was no relevant family history of liver...

Notes

Funding

None.

Compliance with Ethical Standards

Yes.

Patient Consent

Obtained.

Provenance and Peer Review

Not commissioned; externally peer reviewed.

Conflict of Interest

The authors declare that they have no conflict of interest.

Research Involving Human Participants and/or Animals

None.

References

  1. 1.
    Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma-The role of oral contraceptive use. Jr.JAMA. 1979 Aug 17;242(7):644–8  https://doi.org/10.1001/jama.1979.03300070040020
  2. 2.
    Edmondson HA. Tumours of the liver and intrahepatic bile ducts. section 7, fascicle 25. Atlas of tumour pathology. Washington: Armed Forces Institute of Pathology; 1958.Google Scholar
  3. 3.
    Baum BJJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973;2(7835):926–9.  https://doi.org/10.1016/S0140-6736(73)92594-4.CrossRefGoogle Scholar
  4. 4.
    Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception. 1991;43(6):643–52.  https://doi.org/10.1016/0010-7824(91)90007-3.
  5. 5.
    Carrasco D, Barrachina M, Prieto M, Berenguer J. Epidemiology of hepatocellular adenoma-The role of oral contraceptive use. N Engl J Med. 1984;310(17):1120–1.  https://doi.org/10.1056/NEJM198404263101716.CrossRefGoogle Scholar
  6. 6.
    Coombes GB, Reiser J, Paradinas FJ. An androgen-associated hepatic adenoma in a trans-sexual., Burn I. Br J Surg. 1978;65(12):869–70.  https://doi.org/10.1016/0010-7824(91)90007-3.CrossRefGoogle Scholar
  7. 7.
    Fermand JP, Levy Y, Bouscary D, et al. Danazol-induced hepatocellular adenoma. Am J Med. 1990;88(5):529–30.  https://doi.org/10.1016/0002-9343(90)90434-F.CrossRefGoogle Scholar
  8. 8.
    Richter WO, Ritter MM, Wiebecke B, et al. Klinefelter's syndrome and liver adenoma. U. J Clin Gastroenterol. 1991;13(2):214–6.  https://doi.org/10.1097/00004836-199104000-00020
  9. 9.
    Alshak NS, Cocjin J, Podesta L, et al. Hepatocellular adenoma in glycogen storage disease type IV. Arch Pathol Lab Med. 1994;118(1):88–91.  https://doi.org/10.1136/adc.82.6.479.Google Scholar
  10. 10.
    Lack EE, Ornvold K. Focal nodular hyperplasia and hepatic adenoma: a review of eight cases in the pediatric age group. J Surg Oncol. 1986;33(2):129–35.  https://doi.org/10.1002/jso.2930330217.
  11. 11.
    Rosencrantz RA, Wu Y, Sonke PY, et al. Giant hepatocellular adenoma in a previously obese thirteen-year-old boy. Ann Hepatol. 2015;14(4):559–63.Google Scholar
  12. 12.
    Flowers BF, McBurney RP, Vera SR. Ruptured hepatic adenoma. A spectrum of presentation and treatment. Am Surg. 1990;56(6):380–3.Google Scholar
  13. 13.
    Stoot JHMB, Coelen RJS, de Jong MC, et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010;12(8):509–22.  https://doi.org/10.1111/j.1477-2574.2010.00222.x.CrossRefGoogle Scholar
  14. 14.
    Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43(3):515–24.  https://doi.org/10.1002/hep.21068.CrossRefGoogle Scholar
  15. 15.
    Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2):481–9.  https://doi.org/10.1002/hep.22995.CrossRefGoogle Scholar
  16. 16.
    Erdogan D, van Delden OM, Busch OR, et al. Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas. Cardiovasc Intervent Radiol. 2007;30(6):1252–8.  https://doi.org/10.1007/s00270-007-9108-4.CrossRefGoogle Scholar
  17. 17.
    Karkar AM, et al. Management of hepatocellular adenoma: comparison of resection, embolization and observation. HPB (Oxford). 2013;15(3):235–43.  https://doi.org/10.1111/j.1477-2574.2012.00584.x.CrossRefGoogle Scholar
  18. 18.
    Deodhar A, Brody LA, Covey AM, et al. Bland embolization in the treatment of hepatic adenomas: preliminary experience. J Vasc Interv Radiol. 2011;22(6):795–799; quiz 800.  https://doi.org/10.1016/j.jvir.2011.02.027.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Hemant Kumar Singh
    • 1
  • Shraddha Patkar
    • 1
  • A. M. Polnaya
    • 2
  • Mukta Ramadwar
    • 3
  • Mahesh Goel
    • 1
    Email author
  1. 1.Department of Gastroenterology and Hepatobiliary Surgical OncologyTata Memorial HospitalMumbaiIndia
  2. 2.Department of Intervention RadiologyTata Memorial HospitalMumbaiIndia
  3. 3.Department of PathologyTata Memorial HospitalMumbaiIndia

Personalised recommendations